USD 35.1
↓ -0.21 (-0.59%)
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| ATRC | -0.6 | -5.9 | 22.7 | 46.8 | 58.7 | -17.5 | -53.2 | 21.3 | 93.4 | 149.3 |
| S&P 500 | -1.4 | -1.9 | 0.9 | 5.8 | 10.5 | 30.3 | 25.2 | 88.0 | 187.3 | 33111.0 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | ATRC |
| name | AtriCure, Inc. |
| price | 35.1 |
| changes percentage | -0.5947 |
| change | -0.21 |
| day low | 34.68 |
| day high | 35.44 |
| year high | 43 |
| year low | 18.94 |
| market cap | 1711240830 |
| price avg 50 | 29.8994 |
| price avg 200 | 26.9028 |
| exchange | NASDAQ |
| volume | 319382 |
| avg volume | 577989 |
| open | 35.44 |
| previous close | 35.31 |
| eps | -0.83 |
| pe | -42.29 |
| earnings announcement | 2025-02-20T05:00:00.000+0000 |
| shares outstanding | 48753300 |
| timestamp | 2024-11-15 18:13:55 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001323885 | |||
| revenue | 399245000 | 330379000 | 20.84 |
| gross profit | 300370000 | 245940000 | 22.13 |
| gross profit ratio | 0.75 | 0.74 | 1.06 |
| research and development expenses | 73915000 | 57337000 | 28.91 |
| operating expenses | 327053000 | 288609000 | 13.32 |
| interest income | 3792000 | 1994000 | 90.17 |
| interest expense | 6925000 | 4986000 | 38.89 |
| ebitda | -8109000 | -29502000 | 72.51 |
| ebitdaratio | -0.02 | -0.13 | 84.27 |
| operating income | -26683000 | -42669000 | 37.47 |
| operating income ratio | -0.07 | -0.13 | 48.25 |
| net income | -30438000 | -46466000 | 34.49 |
| net income ratio | -0.08 | -0.14 | 45.79 |
| eps | -0.66 | -1.02 | 35.29 |
Revenue Growth: revenue increased to 399 million in 2023 from 330 million in 2022 representing a change of 20.84%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit increased to 300 million in 2023 from 246 million in 2022 representing a change of 22.13%. This indicates a sales profitability growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 74 million in 2023 from 57 million in 2022 representing a change of 28.91%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -8 million in 2023 from -30 million in 2022 representing a change of 72.51%. The increase in EBITDA indicates improved operational efficiency and profitability.
Earnings per Share (EPS): EPS increased to -0.66 in 2023 from -0.66 in 2022 representing a change of 35.29%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Operating Expenses: Operating Expenses increased to 327 million in 2023 from 289 million in 2022 representing a change of 13.32%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Operating Income: Operating income decreased to -27 million in 2023 from -43 million in 2022 representing a change of 37.47%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to -30 million in 2023 from -46 million in 2022 representing a change of 34.49%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001323885 | |||
| revenue | 115910000 | 116269000 | -0.31 |
| gross profit | 86793000 | 86084000 | 0.82 |
| gross profit ratio | 0.75 | 0.74 | 1.14 |
| research and development expenses | 20960000 | 19656000 | 6.63 |
| operating expenses | 94198000 | 93252000 | 1.01 |
| interest income | 1281000 | 997000 | 28.49 |
| interest expense | 1667000 | 1612000 | 3.41 |
| ebitda | -936000 | -1616000 | 42.08 |
| ebitdaratio | -0.01 | -0.02 | 64.45 |
| operating income | -7405000 | -7168000 | -3.31 |
| operating income ratio | -0.06 | -0.06 | -3.63 |
| net income | -7853000 | -8007999 | 1.94 |
| net income ratio | -0.07 | -0.07 | 1.63 |
| eps | -0.17 | -0.17 | 0.00 |
Revenue Growth: revenue decreased to 116 million in 2024Q3 from 116 million in 2024Q2 representing a change of -0.31%. This indicates a sales shrinking, which is a negative sign for the company.
Operating Expenses: Operating Expenses increased to 94 million in 2024Q3 from 93 million in 2024Q2 representing a change of 1.01%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Net Income: Net income decreased to -8 million in 2024Q3 from -8 million in 2024Q2 representing a change of 1.94%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
Gross Profit: Gross Profit increased to 87 million in 2024Q3 from 86 million in 2024Q2 representing a change of 0.82%. This indicates a sales profitability growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 21 million in 2024Q3 from 20 million in 2024Q2 representing a change of 6.63%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -1 million in 2024Q3 from -2 million in 2024Q2 representing a change of 42.08%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -7 million in 2024Q3 from -7 million in 2024Q2 representing a change of -3.31%. The increase in operating income indicates better operational performance and increased profitability.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001323885 | |||
| total assets | 613932000 | 585448000 | 4.87 |
| total liabilities | 147764000 | 128694000 | 14.82 |
| total equity | 466168000 | 456754000 | 2.06 |
| cash and cash equivalents | 84310000 | 58099000 | 45.11 |
| short term investments | 52975000 | 63014000 | -15.93 |
| long term investments | 0 | 51509000 | -100.00 |
| total current assets | 266245999 | 215214000 | 23.71 |
| total non current assets | 347686000 | 370234000 | -6.09 |
| total current liabilities | 74569000 | 58392000 | 27.70 |
| total non current liabilities | 73195000 | 70302000 | 4.12 |
| common stock | 48000 | 47000 | 2.13 |
| retained earnings | -357057000 | -326619000 | -9.32 |
| total debt | 74494000 | 69076000 | 7.84 |
Total Assets: Total Assets increased to 614 million in 2023 from 585 million in 2022 representing a change of 4.87%. Suggesting a growth in asset holdings.
Total Equity: Total Equity increased to 466 million in 2023 from 457 million in 2022 representing a change of 2.06%. This indicates an increase in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 84 million in 2023 from 58 million in 2022 representing a change of 45.11%. This indicates an increase in available liquid assets.
Total Current Assets: Total Current Assets increased to 266 million in 2023 from 215 million in 2022 representing a change of 23.71%. This indicates a better liquidity position.
Common Stock: Common Stock increased to 0 in 2023 from 0 in 2022 representing a change of 2.13%. This indicates an increase in ownership interest.
Total Liabilities: Total Liabilities increased to 148 million in 2023 from 129 million in 2022 representing a change of 14.82%. This indicates an increase in overall liabilities.
Short Term Investments: Short Term Investments decreased to 53 million in 2023 from 63 million in 2022 representing a change of -15.93%. This indicates a decrease in short-term investment holdings.
Total Current Liabilities: Total Current Liabilities increased to 75 million in 2023 from 58 million in 2022 representing a change of 27.7%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -357 million in 2023 from -327 million in 2022 representing a change of -9.32%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 74 million in 2023 from 69 million in 2022 representing a change of 7.84%. This indicates an increase in overall debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001323885 | |||
| total assets | 615068000 | 597273000 | 2.98 |
| total liabilities | 150047000 | 135188000 | 10.99 |
| total equity | 465021000 | 462085000 | 0.64 |
| cash and cash equivalents | 130335000 | 106035000 | 22.92 |
| short term investments | 0 | 7985000 | -100.00 |
| long term investments | 0 | 0 | NaN |
| total current assets | 269286000 | 252852000 | 6.50 |
| total non current assets | 345782000 | 344421000 | 0.40 |
| total current liabilities | 74431000 | 61225000 | 21.57 |
| total non current liabilities | 75616000 | 73963000 | 2.23 |
| common stock | 49000 | 49000 | 0.00 |
| retained earnings | -386187000 | -378334000 | -2.08 |
| total debt | 77128000 | 75316000 | 2.41 |
Total Assets: Total Assets increased to 615 million in 2024Q3 from 597 million in 2024Q2 representing a change of 2.98%. Suggesting a growth in asset holdings.
Total Equity: Total Equity increased to 465 million in 2024Q3 from 462 million in 2024Q2 representing a change of 0.64%. This indicates an increase in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 130 million in 2024Q3 from 106 million in 2024Q2 representing a change of 22.92%. This indicates an increase in available liquid assets.
Total Current Assets: Total Current Assets increased to 269 million in 2024Q3 from 253 million in 2024Q2 representing a change of 6.5%. This indicates a better liquidity position.
Total Liabilities: Total Liabilities increased to 150 million in 2024Q3 from 135 million in 2024Q2 representing a change of 10.99%. This indicates an increase in overall liabilities.
Short Term Investments: Short Term Investments decreased to 0 million in 2024Q3 from 8 million in 2024Q2 representing a change of -100.0%. This indicates a decrease in short-term investment holdings.
Total Current Liabilities: Total Current Liabilities increased to 74 million in 2024Q3 from 61 million in 2024Q2 representing a change of 21.57%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -386 million in 2024Q3 from -378 million in 2024Q2 representing a change of -2.08%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 77 million in 2024Q3 from 75 million in 2024Q2 representing a change of 2.41%. This indicates an increase in overall debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001323885 | |||
| net change in cash | 26211000 | 14445000 | 81.45 |
| operating cash flow | 4484000 | -22141000 | 120.25 |
| free cash flow | -37514000 | -39022000 | 3.86 |
| capital expenditure | -41998000 | -16881000 | -148.79 |
| depreciation and amortization | 14813000 | 11710000 | 26.50 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 35728000 | 28771000 | 24.18 |
| accounts payables | 6177000 | 2677000 | 130.74 |
| inventory | 0 | -7305000 | 100.00 |
| acquisitions net | 0 | -44006000 | 100.00 |
| investments in property plant and equipment | -11998000 | -16881000 | 28.93 |
| net cash used for investing activites | 21817000 | 44006000 | -50.42 |
| debt repayment | -992000 | -899000 | -10.34 |
| common stock issued | 0 | 0 | NaN |
| common stock repurchased | -6557000 | -12201000 | 46.26 |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | -32000 | -7059000 | 99.55 |
| cash at end of period | 84310000 | 58099000 | 45.11 |
| accounts receivables | 0 | -8989000 | 100.00 |
| cash at beginning of period | 58099000 | 43654000 | 33.09 |
Net Change in Cash: Net Change in Cash increased to 26 million in 2023 from 14 million in 2022 representing a change of 81.45%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to 4 million in 2023 from -22 million in 2022 representing a change of 120.25%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to -38 million in 2023 from -39 million in 2022 representing a change of 3.86%. This indicates an increase in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure decreased to -42 million in 2023 from -17 million in 2022 representing a change of -148.79%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Stock-Based Compensation: Stock-Based Compensation increased to 36 million in 2023 from 29 million in 2022 representing a change of 24.18%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables increased to 6 million in 2023 from 3 million in 2022 representing a change of 130.74%. This indicates that the company has increased its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables increased to 0 in 2023 from -9 million in 2022 representing a change of 100.0%. This suggests that the company is less capable of collecting payments from its customers.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001323885 | |||
| operating cash flow | 20004000 | 8240000 | 142.77 |
| free cash flow | 16396000 | 5856000 | 179.99 |
| capital expenditure | -3608000 | -2384000 | -51.34 |
| depreciation and amortization | 4928000 | 4527000 | 8.86 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 10364000 | 10391000 | -0.26 |
| accounts receivables | 893000 | -342000 | 361.11 |
| accounts payables | 4249000 | -2103000 | 302.04 |
| inventory | -2684000 | -1742000 | -54.08 |
| acquisitions net | -25000 | 25000 | -200.00 |
| investments in property plant and equipment | -3608000 | -2384000 | -51.34 |
| net cash used for investing activites | 4392000 | 30891000 | -85.78 |
| debt repayment | -269000 | -264000 | -1.89 |
| common stock issued | 0 | 0 | NaN |
| common stock repurchased | -63000 | -159000 | 60.38 |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | -333000 | 1994000 | -116.70 |
| net change in cash | 24300000 | 41068000 | -40.83 |
| cash at end of period | 130335000 | 106035000 | 22.92 |
| cash at beginning of period | 106035000 | 64967000 | 63.21 |
Net Change in Cash: Net Change in Cash decreased to 24 million in 2024Q3 from 41 million in 2024Q2 representing a change of -40.83%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Accounts Payables: The absolute value of Accounts Payables increased to 4 million in 2024Q3 from 2 million in 2024Q2 representing a change of 302.04%. This indicates that the company has increased its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables increased to 1 in 2024Q3 from 0 million in 2024Q2 representing a change of 361.11%. This suggests that the company is less capable of collecting payments from its customers.
Operating Cash Flow: Operating Cash Flow increased to 20 million in 2024Q3 from 8 million in 2024Q2 representing a change of 142.77%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to 16 million in 2024Q3 from 6 million in 2024Q2 representing a change of 179.99%. This indicates an increase in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure decreased to -4 million in 2024Q3 from -2 million in 2024Q2 representing a change of -51.34%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Stock-Based Compensation: Stock-Based Compensation decreased to 10 million in 2024Q3 from 10 million in 2024Q2 representing a change of -0.26%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 8.62 | 7.22 | 19.36 |
| net income per share | -0.66 | -1.02 | 35.30 |
| operating cash flow per share | 0.1 | -0.48 | 120.00 |
| free cash flow per share | -0.81 | -0.85 | 5.05 |
| cash per share | 2.96 | 2.65 | 11.96 |
| book value per share | 10.07 | 9.99 | 0.81 |
| tangible book value per share | 3.61 | 3.99 | -9.47 |
| shareholders equity per share | 10.07 | 9.99 | 0.81 |
| interest debt per share | 1.51 | 1.4 | 8.18 |
| market cap | 1652768210 | 2029941200 | -18.58 |
| enterprise value | 1642952210 | 2040918200 | -19.50 |
| pe ratio | -54.3 | -43.69 | -24.29 |
| price to sales ratio | 4.14 | 6.14 | -32.62 |
| pocfratio | 368.59 | -91.68 | 502.03 |
| pfcf ratio | -44.06 | -52.02 | 15.31 |
| pb ratio | 3.55 | 4.44 | -20.22 |
| ptb ratio | 3.55 | 4.44 | -20.22 |
| ev to sales | 4.12 | 6.18 | -33.38 |
| enterprise value over ebitda | -202.61 | -69.18 | -192.88 |
| ev to operating cash flow | 366.4 | -92.18 | 497.49 |
| ev to free cash flow | -43.8 | -52.3 | 16.26 |
| earnings yield | -0.02 | -0.02 | 19.55 |
| free cash flow yield | -0.02 | -0.02 | -18.07 |
| debt to equity | 0.14 | 0.13 | 4.88 |
| debt to assets | 0.1 | 0.1 | 2.08 |
| net debt to ebitda | 1.21 | -0.37 | 425.34 |
| current ratio | 3.57 | 3.69 | -3.13 |
| interest coverage | -3.85 | -8.56 | 54.97 |
| income quality | -0.15 | 0.48 | -130.92 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0.19 | 0.17 | 6.68 |
| intangibles to total assets | 0.49 | 0.47 | 3.93 |
| capex to operating cash flow | 9.37 | -0.76 | 1328.46 |
| capex to revenue | 0.11 | 0.05 | 105.87 |
| capex to depreciation | 2.84 | 1.44 | 96.67 |
| stock based compensation to revenue | 0.09 | 0.09 | 2.76 |
| graham number | 12.2 | 15.11 | -19.24 |
| roic | -0.05 | -0.08 | 38.22 |
| return on tangible assets | -0.1 | -0.15 | 35.29 |
| graham net net | 1.36 | 1.04 | 30.94 |
| working capital | 191676999 | 156822000 | 22.23 |
| tangible asset value | 167401000 | 182634000 | -8.34 |
| net current asset value | 118481999 | 86520000 | 36.94 |
| invested capital | 537202999 | 473562000 | 13.44 |
| average receivables | 47597000 | 37857000 | 25.73 |
| average payables | 23626000 | 19247500 | 22.75 |
| average inventory | 56914000 | 42447500 | 34.08 |
| days sales outstanding | 48.0 | 47.17 | 1.76 |
| days payables outstanding | 100.98 | 86.01 | 17.40 |
| days of inventory on hand | 250.64 | 198.54 | 26.24 |
| receivables turnover | 7.6 | 7.74 | -1.73 |
| payables turnover | 3.61 | 4.24 | -14.82 |
| inventory turnover | 1.46 | 1.84 | -20.79 |
| roe | -0.07 | -0.1 | 35.82 |
| capex per share | 0.91 | 0.37 | 145.73 |
ROE: Return on Equity (ROE) increased to -0.07 on 2023-12-31 from -0.10 on 2022-12-31, representing a change of 35.82%. However, ROE is <= 5%, suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -54.30 on 2023-12-31 from -43.69 on 2022-12-31, representing a change of -24.29%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 3.57 on 2023-12-31 from 3.69 on 2022-12-31, representing a change of -3.13%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.14 on 2023-12-31 from 0.13 on 2022-12-31, representing a change of 4.88%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| ATRC | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 2.46 | 2.48 | -0.72 |
| net income per share | -0.17 | -0.17 | 2.34 |
| operating cash flow per share | 0.42 | 0.18 | 141.76 |
| free cash flow per share | 0.35 | 0.12 | 178.82 |
| cash per share | 2.77 | 2.43 | 13.83 |
| book value per share | 9.87 | 9.85 | 0.22 |
| tangible book value per share | 3.65 | 3.56 | 2.46 |
| shareholders equity per share | 9.87 | 9.85 | 0.22 |
| interest debt per share | 1.41 | 1.41 | -0.07 |
| market cap | 1320824200 | 1055452500 | 25.14 |
| enterprise value | 1267617200 | 1024733500 | 23.70 |
| pe ratio | -42.05 | -32.95 | -27.61 |
| price to sales ratio | 11.4 | 9.08 | 25.53 |
| pocfratio | 66.03 | 128.09 | -48.45 |
| pfcf ratio | 80.56 | 180.23 | -55.30 |
| pb ratio | 2.84 | 2.28 | 24.35 |
| ptb ratio | 2.84 | 2.28 | 24.35 |
| ev to sales | 10.94 | 8.81 | 24.09 |
| enterprise value over ebitda | -1354.29 | -634.12 | -113.57 |
| ev to operating cash flow | 63.37 | 124.36 | -49.04 |
| ev to free cash flow | 77.31 | 174.99 | -55.82 |
| earnings yield | -0.01 | -0.01 | 21.64 |
| free cash flow yield | 0.01 | 0.01 | 123.73 |
| debt to equity | 0.14 | 0.14 | -0.36 |
| debt to assets | 0.1 | 0.11 | -2.63 |
| net debt to ebitda | 56.85 | 19.01 | 199.04 |
| current ratio | 3.62 | 4.13 | -12.40 |
| interest coverage | -4.44 | -4.45 | 0.10 |
| income quality | -2.55 | -1.03 | -147.56 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0.18 | 0.17 | 6.96 |
| intangibles to total assets | 0.48 | 0.49 | -3.51 |
| capex to operating cash flow | 0.18 | 0.29 | -37.66 |
| capex to revenue | 0.03 | 0.02 | 51.81 |
| capex to depreciation | 0.73 | 0.53 | 39.03 |
| stock based compensation to revenue | 0.09 | 0.09 | 0.05 |
| graham number | 6.09 | 6.15 | -1.07 |
| roic | -0.01 | -0.01 | -3.71 |
| return on tangible assets | -0.02 | -0.03 | 7.93 |
| graham net net | 1.27 | 1.22 | 3.77 |
| working capital | 194855000 | 191627000 | 1.68 |
| tangible asset value | 171888000 | 167066000 | 2.89 |
| net current asset value | 119239000 | 117664000 | 1.34 |
| invested capital | 537625000 | 532851000 | 0.90 |
| average receivables | 55238500 | 55443500 | -0.37 |
| average payables | 29201000 | 27828500 | 4.93 |
| average inventory | 75100000 | 72799500 | 3.16 |
| days sales outstanding | 42.63 | 43.01 | -0.88 |
| days payables outstanding | 98.1 | 79.51 | 23.38 |
| days of inventory on hand | 236.6 | 219.61 | 7.74 |
| receivables turnover | 2.11 | 2.09 | 0.89 |
| payables turnover | 0.92 | 1.13 | -18.95 |
| inventory turnover | 0.38 | 0.41 | -7.18 |
| roe | -0.02 | -0.02 | 2.55 |
| capex per share | 0.08 | 0.05 | 50.71 |
ROE: Return on Equity (ROE) decreased to -0.02 on 2024-09-30 Q3 from -0.02 on 2024-06-30 Q2, representing a change of 2.55%. Suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -42.05 on 2024-09-30 Q3 from -32.95 on 2024-06-30 Q2, representing a change of -27.61%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 3.62 on 2024-09-30 Q3 from 4.13 on 2024-06-30 Q2, representing a change of -12.40%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.14 on 2024-09-30 Q3 from 0.14 on 2024-06-30 Q2, representing a change of -0.36%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
Negative Sentiment: Discounted Cash Flow value is -18.46 which is lower than current price 35.1, indicates the company may be overvalued.
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2024-10-29 23:53:08
AtriCure, Inc. (NASDAQ:ATRC ) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ET Company Participants Marissa Bych - Investor Relations Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Participants Lilia Lozada - JPMorgan Mike Matson - Needham Danielle Antalffy - UBS Suraj Kalia - Oppenheimer & Co. Operator Good afternoon. And welcome to AtriCure's Third Quarter 2024 Earnings Conference Call.
Sentiment: Positive
Publish Date: 2024-10-29 20:01:13
While the top- and bottom-line numbers for AtriCure (ATRC) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Sentiment: Negative
Publish Date: 2024-10-29 18:11:07
AtriCure (ATRC) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.20 per share a year ago.
Sentiment: Positive
Publish Date: 2024-10-29 16:01:00
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced third quarter 2024 financial results. “Our broad-based growth in the third quarter reflects strong, ongoing adoption trends throughout our business,” said Michael Carrel, President and Chief Executive Officer at AtriCure. “During the quarter, we launched sev.
Sentiment: Negative
Publish Date: 2024-10-16 13:15:25
ATRC's cryoSPHERE MAX probe cuts freeze times by 50%, advancing Cryo Nerve Block therapy to improve post-op pain relief and reduce opioid dependency risks.
Sentiment: Negative
Publish Date: 2024-10-15 08:00:00
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has launched the cryoSPHERE MAX™ cryoablation probe. The cryoSPHERE MAX probe features a larger ball tip designed to optimize Cryo Nerve Block™ therapy (cryoNB). The new probe reduces freeze times by 50% when compared to AtriCure's first generation.
Sentiment: Positive
Publish Date: 2024-10-11 11:30:24
ATRC's EnCompass Clamp receives a CE Mark, enabling European surgeons to access faster, simpler heart ablation in cardiac surgeries with advanced radiofrequency technology.
Sentiment: Negative
Publish Date: 2024-10-08 08:00:00
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its third quarter 2024 financial results on Tuesday, October 29, 2024. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, October 29, 2024, to discuss its third quarter 2024 financial results. Those interested in.
Sentiment: Positive
Publish Date: 2024-09-05 07:23:51
In 2023, the Advanced Technology Research Council (ATRC), an arm of the Abu Dhabi government, spent millions of dollars building a series of large language models. ATRC secretary general Faisal Al Bannai then decided to release them online for free, reasoning that if they were as good as the team’s internal testing showed, it would…
Sentiment: Positive
Publish Date: 2024-08-28 13:15:34
ATRC announces the treatment of the first patient using the AtriClip FLEX-Mini device.
Sentiment: Negative
Publish Date: 2024-08-27 08:00:00
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the first patient was treated with the AtriClip® FLEX-Mini™ device, which recently received 510(k) clearance. The AtriClip FLEX-Mini sets a new standard as the smallest profile surgical LAA device on the market and builds upon the proven technology of.
Sentiment: Neutral
Publish Date: 2024-08-23 13:10:48
AtriCure (ATRC) announces the receipt of an expanded CE-Mark indication for its AtriClip devices for reducing strokes in patients with Afib.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
